John Sheldon, MD
Radiation Oncology · Northampton, MANPI 1467415646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Isoray, Inc at 40.5% of the total. Reporting peaked in 2021 at $101 and has fallen 72.5% since, to $28 in 2025.
Across 5 payments — averaging $49.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Isoray, Inc$101
- Boston Scientific$87
- Myriad Genetic Laboratories, Inc.$33
- Novocure Inc.$28
Across 1 payment — averaging $6839.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$7K
What the payments were for
- Food & beverage$249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Isoray, Inc | 2 | $101 |
| Boston Scientific | 1 | $87 |
| Myriad Genetic Laboratories, Inc. | 1 | $33 |
| Novocure Inc. | 1 | $28 |
How this compares
$249 in reported general payments places this provider in the 60th percentile of 200 radiation oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 32 | $498 |
| Silver Sulfadiazine | 13 | $453 |
| Lidocaine Hcl ViscousLidocaine Hcl | 14 | $291 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Northampton
- Peter OrioBoston$1.8M
- Paul NguyenBoston$721K
- Jason EfstathiouBoston$156K
- Jonathan SchoenfeldBoston$53K
- Martin KingBoston$37K
- Raymond MakBoston$36K
- Shannon MacdonaldBoston$33K
- Nima AghdamBoston$29K
- Rachel JimenezBoston$28K
- Andrea McKeeBurlington$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.